Neyroblastgx LLC
Murrieta, CA
- UEI
- D7H1LWMAP6J3
- CAGE
- 8JSA3
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 26442 Beckman Ct, Murrieta, CA 92562, USA
- Website
- neyroblastgx.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase i: genetically engineered dendritic cell to activate sars-COV-2 spike protein specific-t cell (covid-19) | National Science Foundation | $255,997 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Triterpenoid Therapeutics Inc. | Boston, MA | 813920 Professional Organizations |
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bruker Cellular Analysis, Inc. | Emeryville, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Neurodex Inc. | Natick, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
About the company
Neyroblastgx LLC is a biotechnology company based in Murrieta, CA that focuses on developing next-generation theranostic products for neurodegenerative and infectious diseases such as Alzheimer's disease and COVID-19. It is registered as a sole proprietorship in SAM.gov and has self-certified itself as a Small Disadvantaged Business, Economically Disadvantaged Women Small Owned Business, Woman Owned Small Business, and For Profit Organization.
Neyroblastgx LLC has received prime contract awards from agencies such as the Defense Advanced Research Projects Agency (DARPA) and the Department of the Army Materiel Command Research Development and Engineering Command. Through a $222,673 firm-fixed-price Phase I SBIR contract from DARPA, the company developed HOPSENSE, a human organoid system for detecting pathogens using an electroconductive microfluidic array. It was also awarded a $166,442.51 firm-fixed-price purchase order from the Army for the second monthly technical report under a Phase II STTR research effort related to delivering research and development services. Both contract awards were set aside for Total Small Business.
Neyroblastgx LLC has received a prime federal grant award from the National Science Foundation (NSF). It was awarded a $255,997 Project Grant under the NSF Technology, Innovation, and Partnerships program to support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The grant's period of performance spans from April 2021 to December 2022. This award aims to support the development of a new cellular immunotherapy for COVID-19 through genetic engineering of dendritic cells.
Quick answers
Is Neyroblastgx LLC registered in SAM.gov?
Yes. Neyroblastgx LLC's SAM.gov registration is active through November 22, 2026.
What is Neyroblastgx LLC's most recent federal award?
Neyroblastgx LLC's most recent federal contract award is Hopsense - a human organoid system for detecting pathogens using an electroconductive microfluidic array - base (HR001121C0092), from Defense Advanced Research Projects Agency, on April 1, 2021.
On GovTribe
See Neyroblastgx LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors